Latest Administration News

Advanced Braking Technology (ABT) reported robust FY25 financial results marked by revenue growth and improved profitability, while advancing its strategic roadmap focused on mining safety innovations and global market expansion.

Platinum Asset Management reveals a sharp 86% drop in statutory net profit and a 39% plunge in funds under management for FY25, prompting a cancellation of the final dividend.

Pro Medicus’s U.S. subsidiary Visage Imaging has earned a critical Authority to Operate from the U.S. Department of Veterans’ Affairs, enabling its Visage 7 CloudPACS platform to transition to the Veterans Affairs Enterprise Cloud.

Lumos Diagnostics has secured a significant follow-on contract with Aptatek Biosciences to push forward the development of an innovative in-home monitoring device for Phenylketonuria (PKU), a rare genetic disorder. This next phase aims to bring the FDA Breakthrough Device-designated PheCheck™ closer to clinical trials and commercial readiness.

Amaero Ltd has locked in a five-year exclusive agreement to supply spherical refractory and titanium alloy powders to Titomic, bolstering advanced manufacturing capabilities for defense and aerospace sectors.

Island Pharmaceuticals has formally requested a Type C meeting with the US FDA to discuss accelerating approval of its antiviral Galidesivir for Marburg virus using the Animal Rule pathway.

4DMedical Limited has secured FDA clearance for CT – VQ™, the first non-contrast CT-based ventilation-perfusion imaging technology, promising to transform lung diagnostics by replacing traditional nuclear scans.

PT Aneka Tambang Tbk (ANTAM) reported a remarkable 240% surge in net profit for the half year ended June 30, 2025, driven by robust gold and nickel sales amid a challenging mining sector.

Astron Limited has finalized its move from Hong Kong to Australia, issuing new securities on a two-for-one basis and preparing for ASX trading starting September 1, 2025.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.

Papyrus Australia reported a July 2025 cash flow update showing a stable cash position of AUD 303,000 and available funding supporting operations for over eight months. The company continues to manage its financing facilities prudently while navigating operational expenses.